LOS ANGELES, June 12, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help guide cancer therapy selection, today announced that the National Institutes of Health (NIH) Genetic Testing Registry (GTR), a searchable database of genetic and genomic tests, has been updated to include the recently introduced ResponseDX: Tissue of OriginTM test. Response Genetics acquired this test as part of its acquisition of the assets of the former PathWork Diagnostics in late 2013 and introduced the test, the only FDA-cleared test of its kind, to the market in February 2014. The GTR offers detailed clinical and scientific information about testing options for physicians and patients.
"We are very proud that the GTR has elected to include the ResponseDX: Tissue of OriginTM test, and will soon include all of our other molecular tests in the Response Genetics portfolio", said Thomas A. Bologna, Chairman and Chief Executive Officer of Response Genetics. "A centralized information repository searchable by laboratory, mutation, test, etc. is a tremendous benefit to the community of oncologists, pathologists and patients we serve. In addition to including the basic information about the ResponseDX: Tissue of OriginTM test, namely that is an FDA-cleared, Medicare-reimbursed gene expression analysis that provides a definitive diagnosis for poorly-differentiated or metastatic cancers without a clear primary origin, the GTR also includes detailed information about the test's development, validation and clinical utility making this information easily accessible to physicians, researchers and patients.
"We are very pleased to add Response Genetics' ResponseDX: Tissue of OriginTM test to the GTR, particularly since it is the first test in GTR that is used to identify the tissue in which a malignancy originates," said Wendy Rubinstein, M.D., Ph.D., Director of the Genetic Testing Registry and Senior Scientist at the National Center for Biotechnology Information, a division of the National Library of Medicine at the National Institutes of Health. "Our goal is to provide an efficient means for health care providers, researchers, and others to access detailed information about the broad range of available genetic and genomic tests. The addition of the Response Genetics menu of genomic tests for cancer to our database will significantly further this goal."
Information about the Response Genetics menu can now be found at: http://www.ncbi.nlm.nih.gov/gtr/tests/512726/
To learn more about the GTR, visit http://www.ncbi.nlm.nih.gov/gtr/.
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.